{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:07:13Z","timestamp":1761808033379},"reference-count":9,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.3892\/mco.2016.838","type":"journal-article","created":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T07:34:03Z","timestamp":1459323243000},"page":"1085-1087","source":"Crossref","is-referenced-by-count":5,"title":["Alectinib as a treatment option following recovery from crizotinib-induced interstitial lung disease in patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer"],"prefix":"10.3892","volume":"4","author":[{"given":"SHIGENARI","family":"NUKAGA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KATSUHIKO","family":"NAOKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TETSURO","family":"KAMO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KEITA","family":"MASUZAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HIROYUKI","family":"YASUDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KENZO","family":"SOEJIMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOMOKO","family":"BETSUYAKU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,3,30]]},"reference":[{"key":"key20180107150030_b1-mco-0-0-838","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"key20180107150030_b2-mco-0-0-838","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"key20180107150030_b3-mco-0-0-838","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1200\/JCO.2012.43.3730","article-title":"Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer","volume":"31","author":"Tamiya","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20180107150030_b4-mco-0-0-838","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1470-2045(13)70142-6","article-title":"CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-arm, open-label, phase 1\u20132 study","volume":"14","author":"Seto","year":"2013","journal-title":"Lancet Oncol"},{"key":"key20180107150030_b5-mco-0-0-838","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20180107150030_b6-mco-0-0-838","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/JTO.0000000000000577","article-title":"Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease: A retrospective observational cohort study with a systematic literature review","volume":"10","author":"Cr\u00e9quit","year":"2015","journal-title":"J Thorac Oncol"},{"key":"key20180107150030_b7-mco-0-0-838","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1097\/JTO.0b013e318293dfc1","article-title":"Successful crizotinib retreatment after crizotinib-induced interstitial lung disease","volume":"8","author":"Yanagisawa","year":"2013","journal-title":"J Thorac Oncol"},{"key":"key20180107150030_b8-mco-0-0-838","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","article-title":"Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma","volume":"6","author":"Christensen","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"key20180107150030_b9-mco-0-0-838","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mco.2016.838\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T15:00:39Z","timestamp":1515337239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mco.2016.838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,30]]},"references-count":9,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,3,30]]},"published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.3892\/mco.2016.838"],"URL":"https:\/\/doi.org\/10.3892\/mco.2016.838","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,30]]}}}